Biomarkers in Pulmonary Hypertension

Alberto Maria Marra, Eduardo Bossone, Andrea Salzano, Roberta D'Assante, Federica Monaco, Francesco Ferrara, Michele Arcopinto, Olga Vriz, Toru Suzuki, Antonio Cittadini

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. A multiparametric approach, involving different biomarkers, is preferred because it provides relevant clinical information regarding different organs and body systems. This is especially true in the final stages of PH with its comorbidities and different pathophysiological patterns, supporting that PH is a systemic condition rather than an isolated cardiorespiratory illness.

Original languageEnglish
Pages (from-to)393-402
Number of pages10
JournalHeart Failure Clinics
Volume14
Issue number3
DOIs
Publication statusPublished - Jul 1 2018

Fingerprint

Pulmonary Hypertension
Biomarkers
Disease Progression
Comorbidity
Heart Failure
Therapeutics

Keywords

  • Biomarkers
  • Prognosis
  • Pulmonary hypertension
  • Risk stratification

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Marra, A. M., Bossone, E., Salzano, A., D'Assante, R., Monaco, F., Ferrara, F., ... Cittadini, A. (2018). Biomarkers in Pulmonary Hypertension. Heart Failure Clinics, 14(3), 393-402. https://doi.org/10.1016/j.hfc.2018.03.005

Biomarkers in Pulmonary Hypertension. / Marra, Alberto Maria; Bossone, Eduardo; Salzano, Andrea; D'Assante, Roberta; Monaco, Federica; Ferrara, Francesco; Arcopinto, Michele; Vriz, Olga; Suzuki, Toru; Cittadini, Antonio.

In: Heart Failure Clinics, Vol. 14, No. 3, 01.07.2018, p. 393-402.

Research output: Contribution to journalReview article

Marra, AM, Bossone, E, Salzano, A, D'Assante, R, Monaco, F, Ferrara, F, Arcopinto, M, Vriz, O, Suzuki, T & Cittadini, A 2018, 'Biomarkers in Pulmonary Hypertension', Heart Failure Clinics, vol. 14, no. 3, pp. 393-402. https://doi.org/10.1016/j.hfc.2018.03.005
Marra AM, Bossone E, Salzano A, D'Assante R, Monaco F, Ferrara F et al. Biomarkers in Pulmonary Hypertension. Heart Failure Clinics. 2018 Jul 1;14(3):393-402. https://doi.org/10.1016/j.hfc.2018.03.005
Marra, Alberto Maria ; Bossone, Eduardo ; Salzano, Andrea ; D'Assante, Roberta ; Monaco, Federica ; Ferrara, Francesco ; Arcopinto, Michele ; Vriz, Olga ; Suzuki, Toru ; Cittadini, Antonio. / Biomarkers in Pulmonary Hypertension. In: Heart Failure Clinics. 2018 ; Vol. 14, No. 3. pp. 393-402.
@article{51cca28f9d464a95b6f59b68ad434443,
title = "Biomarkers in Pulmonary Hypertension",
abstract = "Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. A multiparametric approach, involving different biomarkers, is preferred because it provides relevant clinical information regarding different organs and body systems. This is especially true in the final stages of PH with its comorbidities and different pathophysiological patterns, supporting that PH is a systemic condition rather than an isolated cardiorespiratory illness.",
keywords = "Biomarkers, Prognosis, Pulmonary hypertension, Risk stratification",
author = "Marra, {Alberto Maria} and Eduardo Bossone and Andrea Salzano and Roberta D'Assante and Federica Monaco and Francesco Ferrara and Michele Arcopinto and Olga Vriz and Toru Suzuki and Antonio Cittadini",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.hfc.2018.03.005",
language = "English",
volume = "14",
pages = "393--402",
journal = "Heart Failure Clinics",
issn = "1551-7136",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Biomarkers in Pulmonary Hypertension

AU - Marra, Alberto Maria

AU - Bossone, Eduardo

AU - Salzano, Andrea

AU - D'Assante, Roberta

AU - Monaco, Federica

AU - Ferrara, Francesco

AU - Arcopinto, Michele

AU - Vriz, Olga

AU - Suzuki, Toru

AU - Cittadini, Antonio

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. A multiparametric approach, involving different biomarkers, is preferred because it provides relevant clinical information regarding different organs and body systems. This is especially true in the final stages of PH with its comorbidities and different pathophysiological patterns, supporting that PH is a systemic condition rather than an isolated cardiorespiratory illness.

AB - Biomarkers are tools in pulmonary hypertension (PH) management. They may address risk assessment, disease progression, response to medical and surgical therapy, risk of right heart failure, and prognosis. The activation of molecular pathways is the pathophysiological underpinning of the biomarkers assessed in peripheral venous blood. A multiparametric approach, involving different biomarkers, is preferred because it provides relevant clinical information regarding different organs and body systems. This is especially true in the final stages of PH with its comorbidities and different pathophysiological patterns, supporting that PH is a systemic condition rather than an isolated cardiorespiratory illness.

KW - Biomarkers

KW - Prognosis

KW - Pulmonary hypertension

KW - Risk stratification

UR - http://www.scopus.com/inward/record.url?scp=85049334730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049334730&partnerID=8YFLogxK

U2 - 10.1016/j.hfc.2018.03.005

DO - 10.1016/j.hfc.2018.03.005

M3 - Review article

C2 - 29966636

AN - SCOPUS:85049334730

VL - 14

SP - 393

EP - 402

JO - Heart Failure Clinics

JF - Heart Failure Clinics

SN - 1551-7136

IS - 3

ER -